Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 13/2009

01.09.2009 | Therapy in Practice

Management of Ascites

verfasst von: Dr Fedja A. Rochling, Rowen K. Zetterman

Erschienen in: Drugs | Ausgabe 13/2009

Einloggen, um Zugang zu erhalten

Abstract

The development of ascites indicates a pathological imbalance between the production and resorption of intraperitoneal fluid. The appearance and composition of ascites are variable, based on the underlying pathophysiology. Most commonly, ascites develops in the setting of decompensated cirrhosis, peritoneal infection, carcinomatosis, congestive heart failure or a combination (mixed ascites). The diagnosis can be difficult in some patients. Management options for ascites from decompensated liver disease focus on low-sodium diets and diuretics supplemented by large-volume paracentesis, transvenous intrahepatic portosystemic shunts and liver transplantation. The development of refractory ascites, hepatic hydrothorax, hyponatraemia or hepatorenal syndrome presents unique challenges to the provider and the patient. In some of these patients, therapy with liver transplantation will be the only viable therapeutic option. The diagnosis of infectious ascites, such as tuberculosis, and carcinomatous ascites remain diagnostic and therapeutic challenges for the clinician.
Literatur
1.
Runyon BA, Montano AA, Akriviadis EA, et al. The serumascites albumin gradient is superior to the exudatetransudate concept in the differential diagnosis of ascites. Ann Intern Med 1992; 117: 215–20PubMed
2.
Cattau Jr EL, Benjamin SB, Knuff TE, et al. The accuracy of the physical examination in the diagnosis of suspected ascites. JAMA 1982; 247: 1164–6PubMedCrossRef
3.
Lawson JD, Weissbein AS. The puddle sign: an aid in the diagnosis of minimal ascites. N Engl J Med 1959; 260: 652–4PubMedCrossRef
4.
Chongtham DS, Singh MM, Kalantri SP, et al. A simple bedside manoeuvre to detect ascites. Natl Med J India 1997; 10: 13–4PubMed
5.
Williams Jr JW, Simel DL. The rational clinical examination: does this patient have ascites? How to divine fluid in the abdomen. JAMA 1992; 267: 2645–8PubMedCrossRef
6.
Inadomi J, Cello JP, Koch J. Ultrasonographic determination of ascitic volume. Hepatology 1996; 24: 549–51PubMedCrossRef
7.
Chang KJ, Albers CG, Nguyen P. Endoscopic ultrasoundguided fine needle aspiration of pleural and ascitic fluid. Am J Gastroenterol 1995; 90: 148–50PubMed
8.
Sultan J, Robinson S, Hayes N, et al. Endoscopic ultrasonography-detected low-volume ascites as a predictor of inoperability for oesophagogastric cancer. Br J Surg 2008; 95: 1127–30PubMedCrossRef
9.
Krishnan P, Vayoth SO, Dhar P, et al. Laparoscopy in suspected abdominal tuberculosis is useful as an early diagnostic method. ANZ J Surg 2008; 78: 987–9PubMedCrossRef
10.
Bodnar Z, Sipka S, Hajdu Z. The abdominal compartment syndrome (ACS) in general surgery. Hepatogastroenterology 2008; 55: 2033–8PubMed
11.
Meldrum DR, Moore FA, Moore EE, et al. Prospective characterization and selective management of the abdominal compartment syndrome. Am J Surg 1997; 174: 667–72; discussion 672-3PubMedCrossRef
12.
Lui F, Sangosanya A, Kaplan LJ. Abdominal compartment syndrome: clinical aspects and monitoring. Crit Care Clin 2007; 23: 415–33PubMedCrossRef
13.
Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004; 39: 841–56PubMedCrossRef
14.
Runyon BA. Paracentesis of ascitic fluid: a safe procedure. Arch Intern Med 1986; 146: 2259–61PubMedCrossRef
15.
Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000; 32: 142–53CrossRef
16.
Parsi MA, Saadeh SN, Zein NN, et al. Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology 2008; 135: 803–7PubMedCrossRef
17.
Kallwitz ER. Ascites fluid lactoferrin: data emerges for a logical biomarker. Gastroenterology 2008; 135: 731–3PubMedCrossRef
18.
Akriviadis EA. Hemoperitoneum in patients with ascites. Am J Gastroenterol 1997; 92: 567–75PubMed
19.
Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122–8PubMedCrossRef
20.
Planas R, Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006; 4: 1385–94PubMedCrossRef
21.
Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463–72PubMedCrossRef
22.
D’Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31: 468–75PubMedCrossRef
23.
Gines P, Cardenas A, Arroyo V, et al. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646–54PubMedCrossRef
24.
Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776–8PubMedCrossRef
25.
Ros J, Jimenez W, Lamas S, et al. Nitric oxide production in arterial vessels of cirrhotic rats. Hepatology 1995; 21: 554–60PubMed
26.
Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 1139–43PubMedCrossRef
27.
La Villa G, Barletta G, Pantaleo P, et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001; 34: 19–27PubMedCrossRef
28.
Frances R, Benlloch S, Zapater P, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004; 39: 484–91PubMedCrossRef
29.
Frances R, Munoz C, Zapater P, et al. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 2004; 53: 860–4PubMedCrossRef
30.
Grange JD, Amiot X. Nitric oxide and renal function in cirrhotic patients with ascites: from physiopathology to practice. Eur J Gastroenterol Hepatol 2004; 16: 567–70PubMedCrossRef
31.
Greenway CV, Lautt WW. Effects of hepatic venous pressure on transsinusoidal fluid transfer in the liver of the anesthetized cat. Circ Res 1970; 26: 697–703PubMedCrossRef
32.
Laine GA, Hall JT, Laine SH, et al. Transsinusoidal fluid dynamics in canine liver during venous hypertension. Circ Res 1979; 45: 317–23PubMedCrossRef
33.
Granger DN, Miller T, Allen R, et al. Permselectivity of cat blood-lymph barrier to endogenous macromolecules. Gastroenterology 1979; 77: 103–9PubMed
34.
Melgar-Lesmes P, Tugues S, Ros J, et al. Vascular endothelial growth factor and angiopoietin-2 play a major role in the pathogenesis of vascular leakage in cirrhotic rats. Gut 2009; 58: 285–92PubMedCrossRef
35.
Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38: 69–89CrossRef
36.
37.
Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 1991; 114: 886–94PubMed
38.
Pinto-Marques P, Vieira A. Urinary sodium/potassium ratio on random sample as a useful tool to assess diuretic-induced natriuresis on chronic liver disease-associated ascitis. Am J Gastroenterol 2007; 102: 212–3PubMed
39.
Rose LI, Underwood RH, Newmark SR, et al. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 1977; 87: 398–403PubMed
40.
Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–21PubMedCrossRef
41.
Mimidis K, Papadopoulos V, Kartalis G. Eplerenone relieves spironolactone-induced painful gynaecomastia in patients with decompensated hepatitis B-related cirrhosis. Scand J Gastroenterol 2007; 42: 1516–7PubMedCrossRef
42.
Parker LN, Gray DR, Lai MK, et al. Treatment of gynecomastia with tamoxifen: a double-blind crossover study. Metabolism 1986; 35: 705–8PubMedCrossRef
43.
McDermott MT, Hofeldt FD, Kidd GS. Tamoxifen therapy for painful idiopathic gynecomastia. South Med J 1990; 83: 1283–5PubMedCrossRef
44.
Man-Son-Hing M, Wells G. Meta-analysis of efficacy of quinine for treatment of nocturnal leg cramps in elderly people. BMJ 1995; 310: 13–7PubMedCrossRef
45.
Chan P, Huang TY, Chen YJ, et al. Randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension. J Clin Pharmacol 1998; 38: 1151–4PubMed
46.
Roca AO, Jarjoura D, Blend D, et al. Dialysis leg cramps: efficacy of quinine versus vitamin E. ASAIO J 1992; 38: M481–5PubMedCrossRef
47.
Konikoff F, Theodor E. Painful muscle cramps: a symptom of liver cirrhosis? J Clin Gastroenterol 1986; 8: 669–72PubMedCrossRef
48.
Konikoff F, Ben-Amitay G, Halpern Z, et al. Vitamin E and cirrhotic muscle cramps. Isr JMed Sci 1991; 27: 221–3
49.
Serrao M, Rossi P, Cardinali P, et al. Gabapentin treatment for muscle cramps: an open-label trial. Clin Neuropharmacol 2000; 23: 45–9PubMedCrossRef
50.
Hillenbrand P, Sherlock S. Use of metolazone in the treatment of ascites due to liver disease. BMJ 1971 Oct 30; 4(5782): 266–70PubMedCrossRef
51.
Laureno R, Karp BI. Myelinolysis after correction of hyponatremia. Ann Intern Med 1997; 126(1): 57–62PubMed
52.
Sterns RH, Cappuccio JD, Silver SM, et al. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994; 4(8): 1522–30PubMed
53.
Ali F, Guglin M, Vaitkevicius P, et al. Therapeutic potential of vasopressin receptor antagonists. Drugs 2007; 67: 847–58PubMedCrossRef
54.
Palm C, Pistrosch F, Herbrig K, et al. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am J Med 2006; 119: S87–92PubMedCrossRef
55.
Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099–112PubMedCrossRef
56.
Wong F, Blei AT, Blendis LM, et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37: 182–91PubMedCrossRef
57.
Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003; 124: 933–9PubMedCrossRef
58.
Gines P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008; 48: 204–13PubMedCrossRef
59.
Gines P. Vaptans: a promising therapy in the management of advanced cirrhosis. J Hepatol 2007; 46: 1150–2PubMedCrossRef
60.
Gines P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 2008; 48: 1002–10PubMedCrossRef
61.
Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites: results of a randomized study. Gastroenterology 1987; 93: 234–41PubMed
62.
Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493–502PubMed
63.
Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002–10PubMedCrossRef
64.
Appenrodt B, Wolf A, Grunhage F, et al. Prevention of paracentesis-induced circulatory dysfunction: midodrine versus albumin — a randomized pilot study. Liver Int 2008; 28: 1019–25PubMedCrossRef
65.
Singh V, Dheerendra PC, Singh B, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol 2008; 103: 1399–405PubMedCrossRef
66.
67.
Gomez-Cerezo J, Barbado Cano A, Suarez I, et al. Pancreatic ascites: study of therapeutic options by analysis of case reports and case series between the years 1975 and 2000. Am J Gastroenterol 2003; 98: 568–77PubMed
68.
Baron TH. Treatment of pancreatic pseudocysts, pancreatic necrosis, and pancreatic duct leaks. Gastrointest Endosc Clin N Am 2007; 17: 559–79, viiPubMedCrossRef
69.
Oktedalen O, Nygaard K, Osnes M. Somatostatin in the treatment of pancreatic ascites. Gastroenterology 1990; 99: 1520–1PubMed
70.
Bracher GA, Manocha AP, DeBanto JR, et al. Endoscopic pancreatic duct stenting to treat pancreatic ascites. Gastrointest Endosc 1999; 49: 710–5PubMedCrossRef
71.
Telford JJ, Farrell JJ, Saltzman JR, et al. Pancreatic stent placement for duct disruption. Gastrointest Endosc 2002; 56: 18–24PubMedCrossRef
72.
Segal I, Parekh D, Lipschitz J, et al. Treatment of pancreatic ascites and external pancreatic fistulas with a long-acting somatostatin analogue (Sandostatin). Digestion 1993; 54 Suppl. 1: 53–8PubMedCrossRef
73.
Ackerman NB, Sillin LF, Suresh K. Consequences of intraperitoneal bile: bile ascites versus bile peritonitis. Am J Surg 1985; 149: 244–6PubMedCrossRef
74.
Nuzzo G, Giuliante F, Giovannini I, et al. Advantages of multidisciplinary management of bile duct injuries occurring during cholecystectomy. Am J Surg 2008; 195: 763–9PubMedCrossRef
75.
Bridges A, Wilcox CM, Varadarajulu S. Endoscopic management of traumatic bile leaks. Gastrointest Endosc 2007; 65: 1081–5PubMedCrossRef
76.
Bhattacharjya S, Puleston J, Davidson BR, et al. Outcome of early endoscopic biliary drainage in the management of bile leaks after hepatic resection. Gastrointest Endosc 2003; 57: 526–30PubMedCrossRef
77.
Johnston TD, Gates R, Reddy KS, et al. Nonoperative management of bile leaks following liver transplantation. Clin Transplant 2000; 14: 365–9PubMedCrossRef
78.
Kaffes AJ, Hourigan L, De Luca N, et al. Impact of endoscopic intervention in 100 patients with suspected postcholecystectomy bile leak. Gastrointest Endosc 2005; 61: 269–75PubMedCrossRef
79.
Saad WE, Darcy MD. Percutaneous management of biliary leaks: biliary embosclerosis and ablation. Tech Vasc Interv Radiol 2008; 11: 111–9PubMedCrossRef
80.
Puls LE, Duniho T, Hunter JE, et al. The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecol Oncol 1996; 61: 109–12PubMedCrossRef
81.
Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008; 29: 1675–84PubMedCrossRef
82.
Suganuma T, Ino K, Shibata K, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 2005; 11: 2686–94PubMedCrossRef
83.
Zebrowski BK, Liu W, Ramirez K, et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999; 6: 373–8PubMedCrossRef
84.
Mabuchi S, Terai Y, Morishige K, et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res 2008; 14: 7781–9PubMedCrossRef
85.
86.
Kahraman K, Ozguven I, Gungor M, et al. Extremely elevated serum CA-125 level as a result of unruptured unilateral endometrioma: the highest value reported. Fertil Steril 2007; 88: 968: e15-7PubMedCrossRef
87.
Jahsman WE. Chylothorax: a brief review of the literature. Ann Intern Med 1944; 21: 669–78
88.
Aalami OO, Allen DB, Organ Jr CH, et al. Chylous ascites: a collective review. Surgery 2000; 128: 761–78PubMedCrossRef
89.
de Vries GJ, Ryan BM, de Bievre M, et al. Cirrhosis related chylous ascites successfully treated with TIPS. Eur J Gastroenterol Hepatol 2005; 17: 463–6PubMedCrossRef
90.
Zhou DX, Zhou HB, Wang Q, et al. The effectiveness of the treatment of octreotide on chylous ascites after liver cirrhosis. Dig Dis Sci 2009; 54(8): 1783–8PubMedCrossRef
91.
Bhatia C, Pratap U, Slavik Z. Octreotide therapy: a new horizon in treatment of iatrogenic chyloperitoneum. Arch Dis Child 2001; 85: 234–5PubMedCrossRef
92.
Matsumoto T, Yamagami T, Kato T, et al. The effectiveness of lymphangiography as a treatment method for various chyle leakages. Br J Radiol 2009; 82: 286–90PubMedCrossRef
93.
Yamagami T, Masunami T, Kato T, et al. Spontaneous healing of chyle leakage after lymphangiography. Br J Radiol 2005; 78: 854–7PubMedCrossRef
94.
Ji JS, Chae HS, Cho YS, et al. Myxedema ascites: case report and literature review. J Korean Med Sci 2006; 21: 761–4PubMedCrossRef
95.
Parving HH, Hansen JM, Nielsen SL, et al. Mechanisms of edema formation in myxedema: increased protein extravasation and relatively slow lymphatic drainage. N Engl J Med 1979; 301: 460–5PubMedCrossRef
96.
Wilcox CM, Forsmark CE, Darragh T, et al. High-protein ascites in patients with the acquired immunodeficiency syndrome. Gastroenterology 1991; 100: 745–8PubMed
97.
Leal R, Lewin M, Ahmad I, et al. Peritoneal Kaposi’s sarcoma: a cause of ascites in acquired immunodeficiency syndrome. Dig Dis Sci 1994; 39: 206–8PubMedCrossRef
98.
Maida I, Nunez M, Rios MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006; 42: 177–82PubMedCrossRef
99.
Israelski DM, Skowron G, Leventhal JP, et al. Toxoplasma peritonitis in a patient with acquired immunodeficiency syndrome. Arch Intern Med 1988; 148: 1655–7PubMedCrossRef
100.
Hulnick DH, Megibow AJ, Naidich DP, et al. tuberculosis: CT evaluation. Radiology 1985; 157: 199–204PubMed
101.
Jamidar PA, Campbell DR, Fishback JL, et al. Peritoneal coccidioidomycosis associated with human immunodeficiency virus infection. Gastroenterology 1992; 102: 1054–8PubMed
102.
Magliocco A, Miller K, Robertson DI, et al. Occurrence of Pneumocystis carinii organisms in a peritoneal effusion from a patient with the acquired immunodeficiency syndrome. Diagn Cytopathol 1991; 7: 540–2PubMedCrossRef
103.
Moore EH, Russell LA, Klein JS, et al. Bacillary angiomatosis in patients with AIDS: multiorgan imaging findings. Radiology 1995; 197: 67–72PubMed
104.
105.
Pickhardt PJ, Bhalla S. Primary neoplasms of peritoneal and sub-peritoneal origin: CT findings. Radiographics 2005; 25: 983–95PubMedCrossRef
106.
Levy AD, Arnaiz J, Shaw JC, et al. From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. Radiographics 2008; 28: 583–607; quiz 621-2PubMedCrossRef
107.
Rosenberg SM. Palliation of malignant ascites. Gastroenterol Clin North Am 2006; 35: 189–99, xiPubMedCrossRef
108.
Leveen HH, Christoudias G, Ip M, et al. Peritoneo-venous shunting for ascites. Ann Surg 1974; 180: 580–91PubMedCrossRef
109.
Lund RH, Moritz MW. Complications of Denver peritoneovenous shunting. Arch Surg 1982; 117: 924–8PubMedCrossRef
110.
Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 2006; 42: 589–97PubMedCrossRef
111.
Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg 2004; 198: 999–1011PubMedCrossRef
112.
Burger JA, Ochs A, Wirth K, et al. The transjugular stent implantation for the treatment of malignant portal and hepatic vein obstruction in cancer patients. Ann Oncol 1997; 8: 200–2PubMedCrossRef
113.
Won JY, Choi SY, Ko HK, et al. Percutaneous peritoneovenous shunt for treatment of refractory ascites. J Vasc Interv Radiol 2008; 19: 1717–22PubMedCrossRef
114.
Seike M, Maetani I, Sakai Y. Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis. J Gastroenterol Hepatol 2007; 22: 2161–6PubMedCrossRef
115.
Clara R, Righi D, Bortolini M, et al. Role of different techniques for the placement of Denver peritoneovenous shunt (PVS) in malignant ascites. Surg Laparosc Endosc Percutan Tech 2004; 14: 222–5PubMedCrossRef
116.
Sanai FM, Bzeizi KI. Systematic review: tuberculous peritonitis — presenting features, diagnostic strategies and treatment. Aliment Pharmacol Ther 2005; 22: 685–700PubMedCrossRef
117.
Quantrill SJ, Woodhead MA, Bell CE, et al. Peritoneal tuberculosis in patients receiving continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2001; 16: 1024–7PubMedCrossRef
118.
Aguado JM, Pons F, Casafont F, et al. Tuberculous peritonitis: a study comparing cirrhotic and noncirrhotic patients. J Clin Gastroenterol 1990; 12: 550–4PubMedCrossRef
119.
Chow KM, Chow VC, Hung LC, et al. Tuberculous peritonitis-associated mortality is high among patients waiting for the results of mycobacterial cultures of ascitic fluid samples. Clin Infect Dis 2002; 35: 409–13PubMedCrossRef
120.
Wang HK, Hsueh PR, Hung CC, et al. Tuberculous peritonitis: analysis of 35 cases. J Microbiol Immunol Infect 1998; 31: 113–8PubMed
121.
Larsen MV, Sorensen IJ, Thomsen VO, et al. Re-activation of bovine tuberculosis in a patient treated with infliximab. Eur Respir J 2008; 32: 229–31PubMedCrossRef
122.
Hillebrand DJ, Runyon BA, Yasmineh WG, et al. Ascitic fluid adenosine deaminase insensitivity in detecting tuberculous peritonitis in the United States. Hepatology 1996; 24: 1408–12PubMedCrossRef
123.
Mishra OP, Kumar R, Ali Z, et al. Evaluation of polymerase chain reaction and adenosine deaminase assay for the diagnosis of tuberculous effusions in children. Arch Dis Child 2006; 91: 985–9PubMedCrossRef
124.
Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest 2007; 131: 1898–906PubMedCrossRef
125.
Bhargava DK, Shriniwas, Chopra P, et al. Peritoneal tuberculosis: laparoscopic patterns and its diagnostic accuracy. Am J Gastroenterol 1992; 87: 109–12PubMed
126.
Demir K, Okten A, Kaymakoglu S, et al. Tuberculous peritonitis: reports of 26 cases, detailing diagnostic and therapeutic problems. Eur J Gastroenterol Hepatol 2001; 13: 581–5PubMedCrossRef
127.
American Thoracic Society; CDC; Infectious Disease Society of America. Treatment of tuberculosis [published erratum appeared in MMWR Recomm Rep 2005; 53 (51): 1203]. MMWR Recomm Rep 2003; 52: 1–77
128.
Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603–62PubMedCrossRef
129.
Marshall JB. Tuberculosis of the gastrointestinal tract and peritoneum. Am J Gastroenterol 1993; 88: 989–99PubMed
130.
Lannigan R, Hardy G, Tanton R, et al. Chlamydia trachomatis peritonitis and ascites following appendectomy. CMAJ 1980; 123: 295–6
131.
Shabot JM, Roark GD, Truant AL. Chlamydia trachomatis in the ascitic fluid of patients with chronic liver disease. Am J Gastroenterol 1983; 78: 291–4PubMed
132.
Tsukada Y, Tamura S, Mitsuhashi H, et al. Advanced peritonitis and subclinical disseminated intravascular coagulopathy associated with Chlamydia trachomatis infection. Scand J Infect Dis 2001; 33: 555–7PubMedCrossRef
133.
Albert-Braun S, Venema F, Bausch J, et al. Cryptococcus neoformans peritonitis in a patient with alcoholic cirrhosis: case report and review of the literature. Infection 2005; 33: 282–8PubMedCrossRef
134.
Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25: 107–31PubMed
135.
Mandell IN, Ahem MJ, Kliger AS, et al. Candida peritonitis complicating peritoneal dialysis: successful treatment with low dose amphotericin B therapy. Clin Nephrol 1976; 6: 492–6PubMed
136.
Madariaga MG, Tenorio A, Proia L. Trichosporon inkin peritonitis treated with caspofungin. J Clin Microbiol 2003; 41: 5827–9PubMedCrossRef
137.
Fritz JM, Brielmaier BD, Dubberke ER. Micafungin for the prophylaxis and treatment of Candida infections. Expert Rev Anti Infect Ther 2008; 6: 153–62PubMedCrossRef
138.
De la Torre P, Reboli AC. Anidulafungin: a new echinocandin for candidal infections. Expert Rev Anti Infect Ther 2007; 5: 45–52PubMedCrossRef
139.
Fourtounas C, Marangos M, Kalliakmani P, et al. Treatment of peritoneal dialysis related fungal peritonitis with caspofungin plus amphotericin B combination therapy. Nephrol Dial Transplant 2006; 21: 236–7PubMedCrossRef
140.
Jovaisas A, Kraag G. Acute gastrointestinal manifestations of systemic lupus erythematosus. Can J Surg 1987; 30: 185–8PubMed
141.
Iyer S, Afshar K, Sharma OP. Peritoneal and pleural sarcoidosis: an unusual association-review and clinical report. Curr Opin Pulm Med 2008; 14: 481–7PubMedCrossRef
142.
Hoffman BI, Katz WA. The gastrointestinal manifestations of systemic lupus erythematosus: a review of the literature. Semin Arthritis Rheum 1980; 9: 237–47PubMedCrossRef
143.
Kageyama Y, Yagi T, Miyairi M. Systemic lupus erythematosus associated with massive ascites and pleural effusion in a patient who presented with disseminated intravascular coagulation. Intern Med 2002; 41: 161–6PubMedCrossRef
144.
Herve F, Heron F, Levesque H, et al. Ascites as the first manifestation of polyarteritis nodosa. Scand J Gastroenterol 2006; 41: 493–5PubMedCrossRef
145.
Salman MC, Basaran A, Guler T, et al. Meigs’ syndrome with highly elevated ca. 125 levels in a patient with Takayasu arteritis: a case report. Arch Gynecol Obstet 2005; 272: 90–2CrossRef
146.
Han SW, Kim GW, Lee J, et al. Successful treatment with stent angioplasty for Budd-Chiari syndrome in Behcet’s disease. Rheumatol Int 2005; 25: 234–7PubMedCrossRef
147.
Zen Y, Sunagozaka H, Tsuneyama K, et al. Incomplete septal cirrhosis associated with Wegener’s granulomatosis. Liver 2002; 22: 388–93PubMedCrossRef
148.
Burack WR, Hollister RM. Tuberculous peritonitis: a study of forty-seven proved cases encountered by a general medical unit in twenty-five years. Am J Med 1960; 28: 510–23PubMedCrossRef
149.
Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1988; 8: 1104–9PubMedCrossRef
150.
151.
Tueche SG, Pector JC. Peritoneovenous shunt in malignant ascites: the Bordet Institute experience from 1975–1998. Hepatogastroenterology 2000; 47: 1322–4PubMed
152.
Stanley MM. Treatment of intractable ascites in patients with alcoholic cirrhosis by peritoneovenous shunting (LeVeen). Med Clin North Am 1979; 63: 523–36PubMed
153.
Tawes Jr RL, Sydorak GR, Kennedy PA, et al. Coagulopathy associated with peritoneovenous shunting. Am J Surg 1981; 142: 51–5PubMedCrossRef
154.
Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701–7PubMedCrossRef
155.
Salerno F, Merli M, Riggio O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40: 629–35PubMedCrossRef
156.
Gines P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 1839–47PubMedCrossRef
157.
Sanyal AJ, Genning C, Reddy KR, et al. The North American study for the treatment of refractory ascites. Gastroenterology 2003; 124: 634–41PubMedCrossRef
158.
Salerno F, Camma C, Enea M, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133: 825–34PubMedCrossRef
159.
Angeli P, Volpin R, Piovan D, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998; 28: 937–43PubMedCrossRef
160.
Kalambokis G, Fotopoulos A, Economou M, et al. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol 2007; 46: 213–21PubMedCrossRef
161.
Tandon P, Tsuyuki RT, Mitchell L, et al. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int 2009; 29(2): 169–74PubMedCrossRef
162.
Lenaerts A, Van Cauter J, Moukaiber H, et al. Treatment of refractory ascites with clonidine and spironolactone. Gastroenterol Clin Biol 1997; 21: 524–5PubMed
163.
Lenaerts A, Codden T, Meunier JC, et al. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. Hepatology 2006; 44: 844–9PubMedCrossRef
164.
165.
Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403–9PubMedCrossRef
166.
Soriano G, Guarner C, Tomas A, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992; 103: 1267–72PubMed
167.
Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229–36PubMed
168.
Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164–76CrossRef
169.
Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56(9): 1310–8PubMed
170.
Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55–64PubMedCrossRef
171.
Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 2006; 24: 935–44PubMedCrossRef
172.
Hadengue A, Gadano A, Moreau R, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565–70PubMedCrossRef
173.
Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18: 152–6PubMedCrossRef
174.
Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360–8PubMedCrossRef
175.
Martin-Llahi M, Pepin MN, Guevara M, et al. Terlipressin and albumin versus albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352–9PubMedCrossRef
176.
Morrow CS, Kantor M, Armen RN. Hepatic hydrothorax. Ann Intern Med 1958; 49: 193–203PubMed
177.
Cardenas A, Arroyo V. Management of ascites and hepatic hydrothorax. Best Pract Res Clin Gastroenterol 2007; 21: 55–75PubMedCrossRef
178.
Cardenas A, Kelleher T, Chopra S. Review article: hepatic hydrothorax. Aliment Pharmacol Ther 2004; 20: 271–9PubMedCrossRef
179.
Gur C, Ilan Y, Shibolet O. Hepatic hydrothorax: pathophysiology, diagnosis and treatment — review of the literature. Liver Int 2004; 24: 281–4PubMedCrossRef
180.
Roussos A, Philippou N, Mantzaris GJ, et al. Hepatic hydrothorax: pathophysiology diagnosis and management. J Gastroenterol Hepatol 2007; 22: 1388–93PubMedCrossRef
181.
Gordon FD, Anastopoulos HT, Crenshaw W, et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 1997; 25: 1366–9PubMedCrossRef
182.
Spencer EB, Cohen DT, Darcy MD. Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax. J Vasc Interv Radiol 2002; 13: 385–90PubMedCrossRef
183.
Siegerstetter V, Deibert P, Ochs A, et al. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol 2001; 13: 529–34PubMedCrossRef
184.
Strauss RM, Martin LG, Kaufman SL, et al. Transjugular intrahepatic portal systemic shunt for the management of symptomatic cirrhotic hydrothorax. Am J Gastroenterol 1994; 89: 1520–2PubMed
185.
Moskovitz M. The peritoneovenous shunt: expectations and reality. Am J Gastroenterol 1990; 85: 917–29PubMed
186.
Mouroux J, Perrin C, Venissac N, et al. Management of pleural effusion of cirrhotic origin. Chest 1996; 109: 1093–6PubMedCrossRef
187.
Ferrante D, Arguedas MR, Cerfolio RJ, et al. Videoassisted thoracoscopic surgery with talc pleurodesis in the management of symptomatic hepatic hydrothorax. Am J Gastroenterol 2002; 97: 3172–5PubMedCrossRef
188.
Cerfolio RJ, Bryant AS. Efficacy of video-assisted thoracoscopic surgery with talc pleurodesis for porous diaphragm syndrome in patients with refractory hepatic hydrothorax. Ann Thorac Surg 2006; 82: 457–9PubMedCrossRef
189.
Ibi T, Koizumi K, Hirata T, et al. Diaphragmatic repair of two cases of hepatic hydrothorax using video-assisted thoracoscopic surgery. Gen Thorac Cardiovasc Surg 2008; 56: 229–32PubMedCrossRef
Metadaten
Titel
Management of Ascites
verfasst von
Dr Fedja A. Rochling
Rowen K. Zetterman
Publikationsdatum
01.09.2009
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 13/2009
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/11316390-000000000-00000

Weitere Artikel der Ausgabe 13/2009

Drugs 13/2009 Zur Ausgabe

Review Article

Interactions Between Herbal Medicines and Prescribed Drugs

Adis Drug Evaluation

Rivaroxaban

Adis Drug Evaluation

Aprepitant

Current Opinion

Advanced-Stage Follicular Lymphoma in the Rituximab Era

Adis Drug Evaluation

Salmeterol/Fluticasone Propionate

Review Article

Fixed-Dose Combinations as Initial Therapy for Hypertension